Spine Surgery and Related Research
Online ISSN : 2432-261X
ISSN-L : 2432-261X
The effects of minodronate and activated vitamin D on bone mineral density and muscle mass in postmenopausal women with osteoporosis
Kazuki FujimotoKazuhide InageToru ToyoguchiYawara EguchiSumihisa OritaKazuyo YamauchiMiyako SuzukiGou KubotaTakeshi SainohJun SatoYasuhiro ShigaKoki AbeHirohito KanamotoMasahiro InoueHideyuki KinoshitaMasaki NorimotoTomotaka UmimuraMasao KodaTakeo FuruyaJunichi NakamuraTsutomu AkazawaAtsushi TerakadoKazuhisa TakahashiSeiji Ohtori
Author information

2018 Volume 2 Issue 2 Pages 148-153


Introduction: Osteoporosis and sarcopenia are said to be similar disorders. However, few reports have described the effects of anti-osteoporosis drugs on muscle mass in clinical practice.

Methods: We selected 150 postmenopausal women with osteoporosis treated by minodronate (osteoporosis medication [OM] group) and 50 postmenopausal women without osteoporosis who did not receive treatment (no osteoporosis [NO] group). The OM group was further divided into two treatment subgroups: a combination of monthly minodronate and daily activated vitamin D vs. monthly minodronate alone. We measured lumbar spine and femoral neck bone mineral density (BMD) with dual-energy X-ray absorptiometry and muscle mass of the upper limbs, lower limbs, and trunk with bioelectrical impedance analysis at baseline and after 6 months.

Results: The OM and NO groups contained 130 and 37 patients, respectively (mean age: 73.9 ± 8.3 and 74.1 ± 10.0 years, respectively). In the OM group, lumbar spine BMD significantly increased after 6 months, while lower limb muscle mass significantly decreased. In the NO group, lumbar spine BMD and lower limb muscle mass did not significantly change after 6 months. In the OM group, BMD of the lumbar spine significantly increased but the lower limb muscle mass significantly decreased after 6 months relative to the NO group. In the combination therapy subgroup of the OM group muscle mass decreased significantly less than in the minodronate-alone subgroup.

Conclusions: In postmenopausal women with osteoporosis, minodronate can increase BMD but cannot increase muscle mass. However, simultaneous use of activated vitamin D can suppress muscle mass decrease. The combination of activated vitamin D and minodronate may be useful for treating osteoporosis in postmenopausal women.

Fullsize Image
Information related to the author
© 2018 The Japanese Society for Spine Surgery and Related Research.

SSRR is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. Anyone may download, reuse, copy, reprint, or distribute articles published in the journal for not-for-profit purposes if they cite the original authors and source properly. If you remix, transform, or build upon the material, you may not distribute the modified material.
Previous article Next article